Caris Precision Oncology Alliance Continues to Grow Internationally as it Welcomes Curie Oncology from Singapore
Curie Oncology expands Caris collaborative network of oncology institutions focused on research into personalized therapies through precision medicine
News provided by
Share this article
IRVING, Texas, March 9, 2021 /PRNewswire/
Caris Life Sciences®, a leading innovator in molecular science and artificial intelligence focused on fulfilling the promise of precision medicine, announced today that Curie Oncology from Singapore has joined Caris Precision Oncology Alliance™ (POA). The POA is a collaborative network of leading cancer centers that work together to advance comprehensive cancer profiling and establish standards of care for molecular testing in oncology through research focused on predictive and prognostic markers that improve clinical outcomes of cancer patients.
Share this article
Share this article
IRVING, Texas, Feb. 16, 2021 /PRNewswire/ Caris Life Sciences®, a leading innovator in molecular science and artificial intelligence focused on fulfilling the promise of precision medicine, announced today that the Dana-Farber Cancer Institute (Dana-Farber) has joined Caris Precision Oncology Alliance™ (The Alliance/POA). The Alliance is a collaborative network of leading cancer centers that work together to advance comprehensive cancer profiling and establish standards for molecular testing in oncology through research focused on predictive and prognostic markers that improve the clinical outcomes of patients with cancer. At Dana-Farber, it will operate out of the Lank Center for Genitourinary Oncology.